Johnson & Johnson (NYSE:JNJ) Position Trimmed by Trinity Financial Advisors LLC

Trinity Financial Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, Holdings Channel reports. The firm owned 2,704 shares of the company’s stock after selling 86 shares during the quarter. Trinity Financial Advisors LLC’s holdings in Johnson & Johnson were worth $389,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Bright Futures Wealth Management LLC. lifted its stake in shares of Johnson & Johnson by 2.9% in the 2nd quarter. Bright Futures Wealth Management LLC. now owns 3,389 shares of the company’s stock worth $495,000 after acquiring an additional 94 shares during the period. Sachetta LLC boosted its stake in Johnson & Johnson by 5.6% during the 2nd quarter. Sachetta LLC now owns 6,797 shares of the company’s stock valued at $1,097,000 after purchasing an additional 359 shares in the last quarter. Andra AP fonden increased its position in shares of Johnson & Johnson by 144.0% during the 2nd quarter. Andra AP fonden now owns 461,200 shares of the company’s stock valued at $67,409,000 after purchasing an additional 272,200 shares during the period. Doheny Asset Management CA lifted its holdings in shares of Johnson & Johnson by 65.1% in the second quarter. Doheny Asset Management CA now owns 16,327 shares of the company’s stock valued at $2,296,000 after buying an additional 6,437 shares during the period. Finally, First Interstate Bank boosted its stake in Johnson & Johnson by 4.3% during the second quarter. First Interstate Bank now owns 9,260 shares of the company’s stock valued at $1,353,000 after buying an additional 384 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Bank of America reaffirmed a “neutral” rating and issued a $166.00 price target on shares of Johnson & Johnson in a report on Tuesday, December 10th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Stock Down 0.1 %

JNJ traded down $0.20 on Friday, reaching $142.07. 8,585,174 shares of the company traded hands, compared to its average volume of 7,666,985. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $342.05 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 2.52 and a beta of 0.51. The stock’s 50 day moving average price is $150.03 and its 200-day moving average price is $156.04.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the company earned $2.66 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.49%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.